Maureen A. Gannon, PhD
Tuesday’s ADA Presidents Oral Session will highlight this year’s top eight abstracts as selected by the Scientific Sessions Meeting Planning Committee. The two-hour session, which will bring the 77th Scientific Sessions to a close, will begin at 9:45 a.m. in Ballroom 20D.
“This is the one session to give you the deepest appreciation for the depth and the breadth of high-quality diabetes research being conducted and presented at the Scientific Sessions,” said Maureen A. Gannon, PhD, Chair of the 77th Scientific Sessions Meeting Planning Committee.
Five of the meeting’s theme areas—Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education, and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; and Integrated Physiology/Obesity—will be represented with an oral presentation during the session.
Brenda Montgomery, RN, MSHS, CDE, from AstraZeneca, and Alvin C. Powers, MD, from Vanderbilt University School of Medicine, will co-chair the session, which will be the final of more than 2,500 original oral and poster research presentations during the five-day run of the Scientific Sessions.
ADA Presidents Oral Session
9:45 a.m.–11:45 a.m. Tuesday, Ballroom 20D
FEATURED ABSTRACTS
9:45 a.m.
373-OR: Control of Glucose Counterregulation by the Hypothalamic Ventromedial Nucleus
Chelsea L. Kasper
University of Washington
10:00 a.m.
374-OR: Activating Pyruvate Kinase M2 to Prevent the Development of Diabetic Nephropathy
Weier Qi, PhD, Joslin Diabetes Center
10:15 a.m.
375-OR: Discovery and Fine-Mapping of Type 2 Diabetes Susceptibility Loci across Diverse Populations
Hidetoshi Kitajima, MD, PhD, University of Oxford
10:30 a.m.
376-OR: Program ACTIVE II: A Comparative Effectiveness Trial to Treat Major Depression in T2DM
Mary K. de Groot, PhD, Indiana University
10:45 a.m.
377-OR: Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD-REAL Study
Matthew A. Cavender, MD, MPH, FACC, University of North Carolina
11:00 a.m.
378-OR: REMD-477, A Human Glucagon Receptor (GCGR) Antibody, Reduces Daily Insulin Requirements and Improves Glycemic Control in People with Type 1 Diabetes (T1D)
Jeremy Pettus, MD, University of California, San Diego
11:15 a.m.
379-OR: Palmitic Acid Esters of Hydroxy Stearic Acids Reduce Hepatic Glucose Production in Chow and High-Fat Diet (HFD)-Fed Mice
Peng Zhou, PhD, BIDMC, Harvard Medical School
11:30 a.m.
380-OR: Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM)
Leona Plum-Mörschel, MD, Profil
